Literature DB >> 35184269

Factors influencing circulating microRNAs as biomarkers for liver diseases.

Shalini R Dubey1, Tester F Ashavaid2, Philip Abraham1, Minal Umesh Paradkar3.   

Abstract

MicroRNAs (microRNAs) have been implicated to play crucial roles in various liver diseases. Hepatic microRNAs are released in to the circulation in a systematic fashion, and are, therefore, being extensively explored for their role as prognostic or diagnostic markers or therapeutic targets for numerous hepatic diseases. Advantages such as disease- or tissue-specific expression, and ease of detection have implicated circulating microRNAs (c-microRNAs) as the most desirable candidate for biomarker studies. Although several studies have explored c-microRNAs in serum or plasma, consistency of detection of microRNAs remains demanding because of many biological and methodological challenges. Lack of methodological consensus has limited the universal use of c-microRNAs as potential prognostic or diagnostic disease-specific biomarkers. In this review, we have discussed pre-analytical and analytical factors that might affect c-miRNA expression and selection of appropriate data normalization strategy by incorporating endogenous reference microRNAs. This review will aid designing of better approaches and protocols for future diagnostic research on hepatic c-microRNAs.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Data normalization; Endogenous control; Liver disease; MicroRNA; Quantitative polymerase chain reaction; Reference gene

Mesh:

Substances:

Year:  2022        PMID: 35184269     DOI: 10.1007/s11033-022-07170-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  69 in total

Review 1.  Emerging role of microRNAs in liver diseases.

Authors:  Shashi Bala; Miguel Marcos; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

2.  MicroRNAs and Congenital Heart Disease: Where Are We Now?

Authors:  Silvia Pulignani; Maria Grazia Andreassi
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2018-07-25

Review 3.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

Review 4.  Nonalcoholic fatty liver disease in India - a lot done, yet more required!

Authors:  Ajay Duseja
Journal:  Indian J Gastroenterol       Date:  2010-12-30

5.  Circulating microRNAs as potential markers of human drug-induced liver injury.

Authors:  Philip J Starkey Lewis; James Dear; Vivien Platt; Kenneth J Simpson; Darren G N Craig; Daniel J Antoine; Neil S French; Neeraj Dhaun; David J Webb; Eithne M Costello; John P Neoptolemos; Jonathan Moggs; Chris E Goldring; B Kevin Park
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

6.  Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity.

Authors:  Lei Wang; Ning Zhang; Zun Wang; Dong-Mei Ai; Zhen-Yu Cao; Hua-Ping Pan
Journal:  Cell Physiol Biochem       Date:  2016-11-07

7.  Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players.

Authors:  Robert Vincent; Arun Sanyal
Journal:  Curr Pathobiol Rep       Date:  2014-09-01

8.  Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease.

Authors:  Yuhao Zhang; Xixiang Cheng; Zhiqiang Lu; Jingkun Wang; Hongyan Chen; Weiwei Fan; Xin Gao; Daru Lu
Journal:  Diabetes Res Clin Pract       Date:  2012-12-31       Impact factor: 5.602

9.  Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.

Authors:  Carlos J Pirola; Tomas Fernández Gianotti; Gustavo O Castaño; Pablo Mallardi; Julio San Martino; María Mora Gonzalez Lopez Ledesma; Diego Flichman; Faridodin Mirshahi; Arun J Sanyal; Silvia Sookoian
Journal:  Gut       Date:  2014-06-27       Impact factor: 23.059

10.  Different normalization strategies might cause inconsistent variation in circulating microRNAs in patients with hepatocellular carcinoma.

Authors:  Gusheng Tang; Xiaojun Shen; Kaiyang Lv; Yu Wu; Jianwei Bi; Qian Shen
Journal:  Med Sci Monit       Date:  2015-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.